Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verve Therapeutics

5.16
-0.0300-0.58%
Post-market: 5.14-0.0200-0.39%18:51 EDT
Volume:1.81M
Turnover:9.29M
Market Cap:458.19M
PE:-2.20
High:5.26
Open:5.20
Low:4.99
Close:5.19
Loading ...

Verve Therapeutics has positive read from NewAmsterdam data, says Stifel

TIPRANKS
·
11 Dec 2024

Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
30 Nov 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
30 Nov 2024

Bvf Partners Lp Reports 8.2% Passive Stake in Verve Therapeutics Inc as of Nov 11 - SEC Filing

THOMSON REUTERS
·
19 Nov 2024

Verve Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
07 Nov 2024

Verve Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
07 Nov 2024

RBC Capital Adjusts Price Target on Verve Therapeutics to $17 From $20, Maintains Outperform, Speculative Risk Rating

MT Newswires Live
·
06 Nov 2024

Verve Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
06 Nov 2024

Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
06 Nov 2024

Verve Therapeutics (VERV) Receives a Buy from RBC Capital

TIPRANKS
·
06 Nov 2024

Verve Therapeutics Inc : H.c. Wainwright Cuts Target Price to $14 From $15

THOMSON REUTERS
·
06 Nov 2024

Verve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright

TIPRANKS
·
06 Nov 2024

Verve Therapeutics Reports Q3 Progress and Financials

TIPRANKS
·
06 Nov 2024

Verve Therapeutics Positioned for Growth with Promising Clinical Progress and Strategic Expansion

TIPRANKS
·
06 Nov 2024

Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
05 Nov 2024

Verve Therapeutics Ended Q3 2024 With Cash, Cash Equivalents, And Marketable Securities Of $539.9M With Cash Runway Through 2026

Benzinga
·
05 Nov 2024

Verve Therapeutics Q3 2024 GAAP EPS $(0.59) Beats $(0.69) Estimate, Sales $6.87M Beat $2.81M Estimate

Benzinga
·
05 Nov 2024

Verve Therapeutics: Q3 Earnings Snapshot

Associated Press Finance
·
05 Nov 2024

Verve Therapeutics: Expects Capital Position to Be Sufficient to Fund Its Operations Through 2026

THOMSON REUTERS
·
05 Nov 2024

Verve Therapeutics Q3 Collaboration Revenue USD 6.865 Million

THOMSON REUTERS
·
05 Nov 2024